Jacobs Levy Equity Management Inc. Has $614,000 Holdings in Seer, Inc. $SEER

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in Seer, Inc. by 124.5%, owning 363,355 shares valued at $614,000 after acquiring an additional 201,491 shares.
• Seer reported an earnings per share of ($0.33), beating expectations by $0.06, and generated $4.05 million in revenue, surpassing analysts’ expectations of $3.75 million.
• CEO Omid Farokhzad sold 33,992 shares for approximately $69,344, reducing his ownership by 2.60% to 1,272,068 shares valued around $2.6 million.

Jacobs Levy Equity Management Inc. raised its holdings in Seer, Inc. (NASDAQ:SEER - Free Report) by 124.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 363,355 shares of the company's stock after buying an additional 201,491 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.61% of Seer worth $614,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp acquired a new stake in Seer in the 4th quarter valued at approximately $114,000. Dimensional Fund Advisors LP grew its holdings in Seer by 4.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 127,711 shares of the company's stock valued at $295,000 after buying an additional 5,000 shares during the last quarter. Bank of America Corp DE grew its holdings in Seer by 18.3% in the 4th quarter. Bank of America Corp DE now owns 151,337 shares of the company's stock valued at $350,000 after buying an additional 23,411 shares during the last quarter. Northern Trust Corp grew its holdings in Seer by 48.7% in the 4th quarter. Northern Trust Corp now owns 155,617 shares of the company's stock valued at $359,000 after buying an additional 50,992 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Seer by 9.1% in the 4th quarter. Millennium Management LLC now owns 615,812 shares of the company's stock valued at $1,423,000 after buying an additional 51,150 shares during the last quarter. Institutional investors and hedge funds own 75.20% of the company's stock.

Insider Buying and Selling at Seer

In other news, CEO Omid Farokhzad sold 33,992 shares of Seer stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $2.04, for a total transaction of $69,343.68. Following the sale, the chief executive officer owned 1,272,068 shares of the company's stock, valued at approximately $2,595,018.72. This trade represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.28% of the company's stock.

Seer Trading Up 6.8%

SEER traded up $0.14 during midday trading on Thursday, reaching $2.20. The company's stock had a trading volume of 188,931 shares, compared to its average volume of 124,169. The stock has a market cap of $123.95 million, a P/E ratio of -1.58 and a beta of 1.57. The company has a fifty day simple moving average of $2.10 and a 200 day simple moving average of $2.03. Seer, Inc. has a twelve month low of $1.62 and a twelve month high of $2.63.

Seer (NASDAQ:SEER - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.06. Seer had a negative return on equity of 25.10% and a negative net margin of 506.15%.The firm had revenue of $4.05 million for the quarter, compared to analyst estimates of $3.75 million. Sell-side analysts expect that Seer, Inc. will post -1.42 earnings per share for the current year.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.